Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction

Circulation

Volumn 107, Issue 6, 2003, Pages 896-904

  Pacher, Pál ^a   Liaudet, Lucas ^b   Bai, Péter ^a   Mabley, Jon G ^a   Kaminski, Pawel M ^c   Virág, László ^a   Deb, Amitabha ^a   Szabó, Éva ^a   Ungvári, Zoltán ^c   Wolin, Michael S ^c   Groves, John T ^d   Szabó, Csaba ^a,e  

^a INOTEK CORPORATION   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d PRINCETON UNIVERSITY   (United States)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cardiac function; Doxorubicin; Heart failure; Nitric oxide; Oxidative stress

Indexed keywords

3 NITROTYROSINE; AMINOGUANIDINE; ANTINEOPLASTIC AGENT; CREATINE KINASE; DOXORUBICIN; FP 15; LACTATE DEHYDROGENASE; MALONALDEHYDE; METALLOPORPHYRIN; METALLOPROTEINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXYNITRITE; PROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARDIOTOXICITY; CATALYST; CONTROLLED STUDY; CORONARY ARTERY LIGATION; FEMALE; GENE DELETION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID PEROXIDATION; MALE; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY;

ACUTE DISEASE; ANIMALS; CATALYSIS; CHRONIC DISEASE; CREATINE KINASE; DISEASE MODELS, ANIMAL; DOXORUBICIN; ENZYME INHIBITORS; HEART; HEART FAILURE, CONGESTIVE; L-LACTATE DEHYDROGENASE; MALE; METALLOPORPHYRINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PEROXYNITROUS ACID; SURVIVAL RATE;

EID: 0037448784     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000048192.52098.DD     Document Type: Article

References (45)

1. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med. 1974;180:249-259.
2. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305:139-153.
3. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19:817-828.
4. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
5. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
6. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria, II: formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068-3074.
7. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351-375.
8. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994;89:2829-2835.
9. Li T, Singal PK. Adriamycin-induced early changes in myocardial anti-oxidant enzymes and their modulation by probucol. Circulation. 2000;102:2105-2110.
10. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther. 2000;294:396-401.
11. Mihm MJ, Yu F, Weinstein DM, et al. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol. 2002;135:581-588.
12. Mihm MJ, Coyle CM, Schanbacher BL, et al. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res. 2001;49:798-807.
13. Pacher P, Liaudet L, Mabley JG, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol. 2002;40:1006-1016.
14. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther. 2002;300:862-867.
15. Pacher P, Liaudet L, Soriano FG, et al. The role of poly(ADP-ribose) polymerase in the development of cardiovascular dysfunction in diabetes mellitus. Diabetes. 2002;51:514-521.
16. Liaudet L, Murthy KG, Mabley JG, et al. Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide. Infect Immun. 2002;70:192-198.
17. 2 modulate superoxide anion production in bovine cardiac myocytes: potential role of NADH oxidase. Circulation. 1997;96:614-620.
18. Szabó C, Zanchi A, Komjáti K, et al. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type II diabetes and is associated with impaired vascular reactivity. Circulation. 2002;106:2680-2686.
19. Connolly EM, Harmey JH, O'Grady T, et al. Cyclo-oxygenase inhibition reduces turnout growth and metastasis in an orthotopic model of breast cancer. Br J Cancer. 2002;87:231-237.
20. Liaudet L, Yang Z, Al-Affar EB, et al. Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. Mol Med. 2001;7:406-417.
21. Szabó C, Mabley JG, Moeller SM, et al. FP 15, a novel, potent peroxynitrite decomposition catalyst: in vitro cytoprotective actions and protection against diabetes mellitus and diabetic cardiovascular complications. Mol Med. 2002;8:571-580.
22. Siveski-Iliskovic N, Hill M, Chow DA, et al. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995;91:10-15.
23. Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393-397.
24. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett. 1997;411:157-160.
25. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation. 1998;98:1699-1702.
26. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708-1715.
27. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000;101:1833-1839.
28. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
29. Okamoto T, Akaike T, Sawa T, et al. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 2001;276:29596-29602.
30. Ferdinandy P, Danial H, Ambrus I, et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res. 2000;87:241-247.
31. Mostafa AM, Nagi MN, Al Rikabi AC, et al. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats. Res Commun Mol Pathol Pharmacol. 1999;106:193-202.
32. Benyo Z, Kiss G, Szabo C, et al. Importance of basal nitric oxide synthesis in regulation of myocardial blood flow. Cardiovasc Res. 1991;25:700-703.
33. Imondi AR. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. Semin Oncol. 1998;25:22-30.
34. Nelson MA, Frishman WH, Seiter K, et al. Cardiovascular considerations with anthracycline use in patients with cancer. Heart Dis. 2001;3:157-168.
35. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-1437.
36. Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol. 1998;25:15-21.
37. Lee J, Hunt JA, Groves JT. Rapid decomposition of peroxynitrite by manganese porphyrin-antioxidant redox-couples. Bioorg Med Chem Lett. 1997;7:2913-2918.
38. Marla SS, Lee J, Groves JT. Perioxynitrite rapidly permeates phospholipid membranes. Proc Natl Acad Sci U S A. 1997;94:14243.
39. Groves JT, Marla SS. Peroxynitrite-induced DNA strand scission mediated by a manganese porphyrin. J Am Chem Soc. 1995;117:9578.
40. Groves JT. Peroxynitrite: reactive, invasive and enigmatic. Curr Op Chem Biol. 1999;3:226-235.
41. Lee J, Hunt JA, Groves JT. Mechanisms of iron porphyrin reactions with peroxynitrite. J Am Chem Soc. 1998;120:7493-7501.
42. Misko TP, Highkin MK, Veenhuizen AW, et al. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem. 1998;273:15646-15653.
43. Misko TP, Salvemini D, Wang Z-Q, et al. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Nat Acad Sci U S A. 1998;95:2659-2663.
44. Shimanovich R, Groves JT. Mechanisms of peroxynitrite decomposition catalyzed by FeTMPS, a bioactive sulfonated iron porphyrin. Arch Biochem Biophys. 2001;387:307-317.
45. Bianchi C, Wakiyama H, Faro R, et al. A novel peroxynitrite decomposition catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg. 2002;74:1201-1207.